ERCC4 and colorectal cancer: To investigate whether the XPF–ERCC1 blocker can improve the therapeutic efficacy of 5-FU- and oxaliplatin-based CRT in colorectal cancer, we first analyzed the cytotoxicity of the 5-FU, OXA, and XPF–ERCC1 blocker to understand the dose-limitation of each compound.